NCT07178912View on ClinicalTrials.gov

Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 27, 2026

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2031

Conditions
Phase II Clinical TrialBlinatumomabOlverembatinibLymphoblastic LeukemiaPhiladelphia Chromosome Positive
Interventions
DRUG

Blinatumomab

Given by Iv

DRUG

olverembatinib

Given by PO

Trial Locations (1)

77030

MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

Amgen

INDUSTRY

collaborator

Ascentage Pharma Group Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER